Gilead and Merck Report Positive Phase 3 Data for Once-Weekly HIV Treatment

What happened

Gilead and Merck reported positive topline Phase 3 data for their oral once-weekly HIV treatment islatravir/lenacapavir, meeting the primary efficacy endpoint at Week 48 in both ISLEND-1 and ISLEND-2 trials. While this adds a pipeline asset that could eventually contribute to Gilead's HIV franchise, it does not change the immediate commercial focus on the twice-yearly PrEP shot Yeztugo. The news reduces some long-term pipeline risk but does not address the key near-term uncertainties around Yeztugo's payer access, covered lives, and re-dosing persistence. The stock's valuation already reflects high expectations for Yeztugo's 2026 ramp, so this data is unlikely to drive a re-rating until the treatment reaches market. Investors should remain focused on Yeztugo's execution milestones as the primary catalyst for the next 6–12 months.

Implication

The positive Phase 3 results for islatravir/lenacapavir support Gilead's long-term HIV pipeline and may provide a new revenue stream in the treatment market. However, the immediate investment focus should remain on Yeztugo's adoption curve and payer coverage expansions, as the stock's valuation already reflects high expectations for the PrEP launch. Any significant upside from this news is likely muted until the product reaches market, which is years away. Investors should wait for clearer evidence on Yeztugo's ramp before adding to positions.

Thesis delta

The positive Phase 3 data for a once-weekly HIV treatment reduces pipeline risk and adds optionality but does not alter the central thesis that Gilead's near-term value hinges on Yeztugo's commercial success. The likelihood of a material pipeline-driven re-rating in the next 6–12 months remains low.